Drug Trial Radar · NCT05978284
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Oct 27, 2023
Primary completion
Sep 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.
Conditions
- Small Cell Lung Cancer
- Neuroendocrine Carcinoma
Interventions
ZG006Biological
ZG006 will be administered as an intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicity (DLT)Time frame: Up to 28 days
- Maximum Tolerated Dose (MTD) of ZG006Time frame: Up to approximately 1 year
- Determine the Recommended Phase 2 Dose (RP2D)Time frame: Up to approximately 1 year
- Number of participants with adverse events (AEs)Time frame: Up to approximately 2 year
- Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 2 year
- Incidence of abnormal laboratory resultsTime frame: Up to approximately 2 year
- Changes of ECGs from baselinesTime frame: Up to approximately 2 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.